In conclusion, we focused on the potential target genes of the Hippo-YAP pathway, its influence on the occurrence and development of HCC, and the mechanisms involved, suggesting that FHL3 may be a key target for screening or treatment of HCC patients with Hippo-YAP pathway abnormalities. This evidence concerns the gene FHL3 and hepatocellular carcinoma.